News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CyDex Pharmaceuticals Announces Captisol(R) Technology Used in Recently Approved New Premixed Bag Presentation of NEXTERONE(R)


11/19/2010 11:11:50 AM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals’ NEXTERONE® (amiodarone HCL) Premixed Injection, which recently received supplemental new drug application (sNDA) approval from the U.S. Food and Drug Administration, makes use of the patent-protected CyDex Captisol® technology platform. The new product is a premixed intravenous (IV) bag formulation of Prism Pharmaceuticals’ NEXTERONE Injection, which was the first CyDex licensed proprietary product to achieve NDA approval.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES